Actavis Plc ACT.N is in advanced talks to acquire rival drug maker Forest Laboratories Inc FRX.N in a deal that could value Forest at up to $25 billion, the Wall Street Journal reported citing people familiar with the matter.
The deal is expected to be announced as early as Tuesday, but it is possible that the talks could still fall apart, the Journal said. (link.reuters.com/rav86v)
Amanda Kaufman, a Forest Labs spokeswoman, said the company does not comment on market rumors. Reuters could not immediately reach Actavis for comment outside of regular business hours.
A combined Actavis-Forest could offer a range of generic and brand-name medicines, reaping economies of scale of its own, the Journal said.
Actavis competes with larger drugmakers such as Teva Pharmaceuticals Industries Ltd (TEVA.TA) and Mylan Inc (MYL.O).
Actavis has turned to acquiring specialty branded drugs, which have far higher profit margins than generics, to boost earnings.
Forest has a market capitalization of $19.34 billion as of Friday's close, compared with $33.40 billion for Actavis, according to Thomson Reuters data.
Forest had wrangled with billionaire investor Carl Icahn for years and ultimately struck a deal with him last summer that averted a proxy fight. It is still facing patent expirations on several of its biggest drugs, including Namenda, which is prescribed to improve cognitive function in people with Alzheimer's disease.
Forest Chief Executive Brent Saunders, who joined the company last October, would stay at the combined company, the Journal said. Saunders' exact role is still being worked out.
Saunders had earlier been Bausch & Lomb's CEO and previously worked at Schering-Plough Corp, which was bought by Merck & Co (MRK.N) in 2009.
In January, Forest said it would buy specialty pharmaceutical maker Aptalis from private equity firm TPG Capital for $2.9 billion in a deal it promised would increase next year's earnings.
Actavis, which itself was a takeover target, acquired specialty pharmaceutical company Warner Chilcott Plc last year for $5 billion in stock to expand its branded drug portfolio.
(Reporting by Chris Peters in Bangalore; Editing by Supriya Kurane)